Floatz logo

su011248

Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.Phase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Gastrointestinal Stromal Tumors cohort.

Asset / SponsorPhaseRating
Esomeprazole
Erasmus Medical Center
Phase 4BB
CALCIUM PHOSPHATE
Impaqtt Foundation
Phase 3BB
Peginterferon-Alpha 2B ;
University of Utah
Phase 2CCC
Guadecitabine
National Cancer Institute (NCI)
Phase 2CCC
Imatinib
University of Utah
Phase 2CCC

View all 15 →

Same molecule, other indications

su011248 is also rated in:

Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Carcinoma, Small Cell LungDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →